Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Removal in HeartMate 3 LVAD Patients
NCT04069156Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Countries
- 9
01
Overview
Randomised, double-blind trial in heart failure (HF) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events at 12 months. Started Jul 2020; status: completed.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04069156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069156.